Neurocrine reports a second PhIII success in congenital adrenal hyperplasia, this time in children

Neu­ro­crine Bio­sciences said its treat­ment for con­gen­i­tal adren­al hy­per­pla­sia (CAH) — a ge­net­ic dis­or­der that caus­es hor­mone im­bal­ance  — helped re­duce the dai­ly dose of steroids that pe­di­atric pa­tients need­ed while main­tain­ing hor­mone con­trol.

It’s the sec­ond Phase III suc­cess for Neu­ro­crine’s crinecer­font, fol­low­ing a “sol­id” Phase III read­out in adult pa­tients in Sep­tem­ber. Neu­ro­crine is hop­ing to file an ap­pli­ca­tion for ap­proval with the FDA next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.